Hey, I didn't check twitter, but your tweet is at the bottom of the article. What a load of misleading statements and graphs from JNJ. Xtandi hasn't approved in chemo naive CRPC yet, Zytiga has lost market share in chemo treated since Xtandi's approval, but they stated Zytiga increased market share overall since Zytiga's approval in chemo naive.
Market Data 
Markets 
AI
